Novo's Q2 Sales Rose 7%-Why the Real Story Is Whether Wegovy Can Outrun US Price Pressure

Q2 growth was positive, but US price pressure kept the market from relaxing

The message from quarterly results earlier this week and the earnings call yesterday was sober rather than celebratory. Adjusted sales grew 7% in Q2 2026, which is still growth, but not enough to suggest US price pressure has been solved.

Why investors are split

The bullish view is straightforward: this is still a healthy business. Q2 2026 adjusted sales reached DKK 78.5 billion, net profit was DKK 21.0 billion, free cash flow was DKK 42.5 billion, and more than 46 million people globally have been treated for obesity and diabetes. That points to a functioning franchise, not a broken one.

The bearish view focuses on how that growth was achieved. Management attributed part of the quarter to lower realized prices and US pricing pressure. For investors, that is the real issue: discounting can preserve volume for a while, but it does not usually justify a premium valuation.

Wegovy demand still looks intact outside the pricing debate

The clearest operational question is whether the products are still working in practice. If patient demand were cracking, the story would be simpler. What the available evidence suggests instead is that demand is holding up while US pricing and channel dynamics are becoming harder.

The prescription data still supports demand

Wegovy pill captured 90% of the US oral obesity market and delivered more than 5 million cumulative prescriptions in 30 weeks. In Q1, Novo also said the product had generated more than 2 million prescriptions since launch.

That does not look like a fading brand. It suggests patients and clinicians are still engaging with the product, which matters because retention can matter as much as awareness in obesity treatment.

More formats may help keep patients on the same path

Novo is also broadening the ways patients can stay within the Wegovy ecosystem. The company highlighted rapid Wegovy pill uptake in the US, UK, and UAE, and in July the EMA approved the Wegovy 7.2 mg pen and pill.

That does not solve pricing by itself, but it can help with adherence and access. Some patients prefer pills, some prefer injections; offering both gives Novo more flexibility to keep people in treatment.

Product strength and pricing are now two different stories

This is where the bull and bear cases diverge. The product story still looks stronger than a 7% sales growth headline suggests. But strong demand does not automatically translate into better revenue if realized prices keep coming under pressure in the US.

The key watchpoint is whether volume strength and oral uptake can show up more cleanly in revenue. If they do, the market may decide Wegovy can still outrun the pricing reset. If not, Novo will keep looking like a premium product franchise in a tougher US pricing environment.

What investors are really weighing now

The market is not waiting for a miracle. It is trying to decide what kind of company Novo becomes if growth shifts from exceptional to merely very good.

Strong cash flow gives management time, but it is not the thesis

The latest quarter also showed free cash flow of DKK 42.5 billion and an interim dividend of DKK 3.75 per share. That tells investors this is still a cash-generating business, not a distressed one.

Still, cash flow is support, not the main investment case. It helps if the slowdown is a pricing reset. It matters less if the market concludes the premium multiple needs to come down for longer.

What to watch before the next report

The next scheduled update comes when Novo reports the first three quarters of 2026 on 4 November 2026. In the meantime, the most useful signposts are:

• whether US realized prices are stabilizing
• whether obesity GLP-1 volumes are translating more fully into revenue
• whether oral uptake continues to expand without masking deeper pricing weakness

The practical takeaway is simple: this still looks like a hold-and-verify setup. If upcoming commentary shows pricing stabilizing while demand remains firm, the stock could rerate. If discounting appears more entrenched, the market is more likely to treat Novo as a strong business in a less favorable pricing regime.